Precision Psychobiotics for Gut–Brain Axis Health: Advancing the Discovery Pipelines to Deliver Mechanistic Pathways and Proven Health Efficacy DOI Creative Commons
Rebecca F. Slykerman, Naomi Davies, Klára Vlčková

et al.

Microbial Biotechnology, Journal Year: 2025, Volume and Issue: 18(1)

Published: Jan. 1, 2025

ABSTRACT Advancing microbiome–gut–brain axis science requires systematic, rational and translational approaches to bridge the critical knowledge gaps currently preventing full exploitation of gut microbiome as a tractable therapeutic target for gastrointestinal, mental brain health. Current research is still marked by many open questions that undermine widespread application humans. For example, lack mechanistic understanding probiotic effects means it remains unclear why even apparently closely related strains exhibit different in vivo. live microbial psychobiotics, consensus on their adjunct treatments conventional neuromodulators, use unmedicated populations or at‐risk cohorts with sub‐clinical symptomatology warranted. This missing information both sides equation when treating central nervous system (CNS) conditions makes psychobiotic challenging, especially compared other pharmaceutical functional food approaches. Expediting transition from positive preclinical data proven benefits humans includes interpreting promises pitfalls animal behavioural assays, well navigating mechanism‐informed decision making select right microbe(s) job. In this review, we consider how these decisions can be supported light accrued range clinical studies across healthy, pathological study populations, where specific have been evaluated context gastrointestinal physiology, function behaviour. Examples successful, partial unsuccessful translation bench bedside are considered. We also discuss developments silico analyses enhanced our moved towards pinpointing host–microbe interactions most important optimal gut–brain function. Combining assays vitro ex vivo domains incorporating model organisms prime discovery pipelines promising rationally selected candidates.

Language: Английский

What Are the Key Gut Microbiota Involved in Neurological Diseases? A Systematic Review DOI Open Access
Bruno Bonnechère, Najaf Amin, Cornelia M. van Duijn

et al.

International Journal of Molecular Sciences, Journal Year: 2022, Volume and Issue: 23(22), P. 13665 - 13665

Published: Nov. 8, 2022

There is a growing body of evidence highlighting there are significant changes in the gut microbiota composition and relative abundance various neurological disorders. We performed systematic review different altered wide range disorders (Alzheimer’s disease (AD), Parkinson’s (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis, stroke). Fifty-two studies were included representing 5496 patients. At genus level, most frequently involved Akkermansia, Faecalibacterium, Prevotella. The overlap between pathologies was strongest for MS PD, sharing eight genera (Akkermansia, Butyricicoccus, Bifidobacterium, Coprococcus, Dorea, Parabacteroides, Prevotella) PD stroke, six (Enterococcus, Lactobacillus, Prevotella, Roseburia). identification signatures overlapping AD, raise question whether these reflect common etiology or rather consequence diseases. interpretation hampered by low number power ALS, stroke with ample opportunity false positive negative findings.

Language: Английский

Citations

39
Lactobacillus plantarum CCFM405 against Rotenone-Induced Parkinson’s Disease Mice via Regulating Gut Microbiota and Branched-Chain Amino Acids Biosynthesis DOI Open Access

Chuanqi Chu,

Leilei Yu, Yiwen Li

et al.

Nutrients, Journal Year: 2023, Volume and Issue: 15(7), P. 1737 - 1737

Published: April 1, 2023

Recent studies have demonstrated that disturbances in the gut microbiota and -derived metabolites contribute to pathogenesis of Parkinson's disease (PD), suggesting probiotic treatments restore them may delay progression. This study aimed examine attenuating efficacy L. plantarum CCFM405 potential mechanisms mice with rotenone-induced PD. Our results indicate ameliorated motor deficits constipation, decreased dopaminergic neuronal death, reduced intestinal inflammation neuroinflammation, raised dopamine levels, 5-HT, associated striatal region brain Sequencing 16S rRNA from fecal revealed normalized bacterial composition PD, as evidenced by increased relative abundance following genus, Bifidobacterium, Turicibacter, Faecalibaculum, Alistipes, Bilophila, Akkermansia, Escherichia-Shigella. The PICRUSt-predicted function enhanced biosynthesis amino acid pathways, particularly valine, leucine, isoleucine (branched-chain acids, BCAAs). A non-metabolomic analysis serum feces showed markedly levels BCAAs. Pathway enrichment based on KEGG database further suggested supplementation can promote BCAAs biosynthesis. Collectively, help prevent PD modulating microbiota-metabolite axis. play a dominant role CCFM405-associated neuroprotection mice. could be utilized food supplement management

Language: Английский

Citations

35
Effect of Lacticaseibacillus paracasei strain Shirota supplementation on clinical responses and gut microbiome in Parkinson's disease DOI Creative Commons

Xiaodong Yang,

Xiaoqin He,

Shaoqing Xu

et al.

Food & Function, Journal Year: 2023, Volume and Issue: 14(15), P. 6828 - 6839

Published: Jan. 1, 2023

Parkinson's disease (PD) is a common neurodegenerative characterized by motor issues and range of non-motor symptoms. Microbial therapy may be useful approach for the treatment PD. However, comprehensive analyses impact probiotic supplementation on symptoms are still lacking mechanisms whereby works remain unclear. This study investigated Lacticaseibacillus paracasei strain Shirota (LcS) clinical responses, gut microbiota faecal metabolites in PD patients. Patients (n = 128) were randomised to receive either probiotics (LcS-fermented milk, containing 1 × 1010 living LcS cells) or placebo 12 weeks. All participants examined basic features recorded using questionnaires. Fecal blood samples collected at baseline after weeks further omics analysis. We found that intervention significantly alleviated patients' constipation-related no significant shifts composition metabolites. Several taxa differentially abundant between groups, especially with regard intake, which increased abundance genus group compared those group. The concentration L-tyrosine was decreased plasma Our demonstrated although did not induce major changes global microbiome, had favorable effects managing constipation other registered Chinese Clinical Trial Registry: ChiCTR1800016795.

Language: Английский

Citations

34
Exploring the potential impact of probiotic use on drug metabolism and efficacy DOI Creative Commons
Carmen Purdel, Anca Ungurianu, Ines Adam-Dima

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 161, P. 114468 - 114468

Published: March 1, 2023

Probiotics are frequently consumed as functional food and widely used dietary supplements, but also recommended in treating or preventing various gastrointestinal diseases. Therefore, their co-administration with other drugs is sometimes unavoidable even compulsory. Recent technological developments the pharmaceutical industry permitted development of novel drug-delivery systems for probiotics, allowing addition to therapy severely ill patients. Literature data regarding changes that probiotics could impose on efficacy safety chronic medication scarce. In this context, present paper aims review currently by international medical community, evaluate relationship between gut microbiota pathologies high impact worldwide and, most importantly, assess literature reports concerning ability influence pharmacokinetics/pharmacodynamics some drugs, especially those narrow therapeutic indexes. A better understanding potential drug metabolism, contribute improving management, facilitating individualized updating treatment guidelines.

Language: Английский

Citations

32
Correlation between the gut microbiome and neurodegenerative diseases: a review of metagenomics evidence DOI Creative Commons
Xiaoyan Liu, Yi Liu, Junlin Liu

et al.

Neural Regeneration Research, Journal Year: 2023, Volume and Issue: 19(4), P. 833 - 845

Published: Aug. 14, 2023

A growing body of evidence suggests that the gut microbiota contributes to development neurodegenerative diseases via microbiota-gut-brain axis. As a contributing factor, dysbiosis always occurs in pathological changes diseases, such as Alzheimer's disease, Parkinson's and amyotrophic lateral sclerosis. High-throughput sequencing technology has helped reveal bidirectional communication between central nervous system enteric is facilitated by microbiota's diverse microorganisms, for both neuroimmune neuroendocrine systems. Here, we summarize bioinformatics analysis wet-biology validation metagenomics with an emphasis on multi-omics studies virome. The pathogen-associated signaling biomarkers identifying brain disorders potential therapeutic targets are also elucidated. Finally, discuss role diet, prebiotics, probiotics, postbiotics exercise interventions remodeling microbiome reducing symptoms diseases.

Language: Английский

Citations

29
Connecting the Gut Microbiota and Neurodegenerative Diseases: the Role of Bile Acids DOI

Shixu Wang,

Chongchong Xu, Hongyan Liu

et al.

Molecular Neurobiology, Journal Year: 2023, Volume and Issue: 60(8), P. 4618 - 4640

Published: May 1, 2023

Language: Английский

Citations

24
Effect of probiotic supplementation on gastrointestinal motility, inflammation, motor, non-motor symptoms and mental health in Parkinson’s disease: a meta-analysis of randomized controlled trials DOI Creative Commons
Jong Mi Park, Sang Chul Lee,

Chorom Ham

et al.

Gut Pathogens, Journal Year: 2023, Volume and Issue: 15(1)

Published: March 6, 2023

Parkinson's disease (PD) is the second most common neurodegenerative worldwide. Gut dysbiosis hypothesized to cause PD; therefore, whether probiotics can be used as adjuvants in treatment of PD being actively investigated.We performed a systematic review and meta-analysis evaluate effectiveness probiotic therapy patients.PUBMED/MEDLINE, EMBASE, Cochrane, Scopus, PsycINFO Web Science databases were searched till February 20, 2023. The random effects model effect size was calculated mean difference or standardized difference. We assessed quality evidence using Grade Recommendations Assessment, Development Evaluation (GRADE) approach.Eleven studies involving 840 participants included final analysis. This showed high-quality improvement Unified Rating Scale Part III motor scale (standardized [95% confidence interval]) (- 0.65 [- 1.11 - 0.19]), non-motor symptom 0.81 1.12 0.51]), depression 0.70 0.93 -0.46]). Moderate low significant observed gastrointestinal motility (0.83 [0.45-1.10]), life 1.02 1.66 0.37]), anxiety 0.72 1.10 0.35]), serum inflammatory markers 5.98 9.20 2.75]), diabetes risk 3.46 4.72 2.20]). However, there no improvements Bristol Stool scores, constipation, antioxidant capacity, dyslipidemia. In subgroup analysis, capsules improved compared fermented milk.Probiotic supplements may suitable for improving symptoms reducing depression. Further research warranted determine mechanism action optimal protocol.

Language: Английский

Citations

23
The gut microbiota–brain axis in neurological disorders DOI Creative Commons

Mingming You,

Nan Chen,

Yuanyuan Yang

et al.

MedComm, Journal Year: 2024, Volume and Issue: 5(8)

Published: July 20, 2024

Abstract Previous studies have shown a bidirectional communication between human gut microbiota and the brain, known as microbiota–gut–brain axis (MGBA). The MGBA influences host's nervous system development, emotional regulation, cognitive function through neurotransmitters, immune modulation, metabolic pathways. Factors like diet, lifestyle, genetics, environment shape composition together. Most research explored how regulates host physiology its potential in preventing treating neurological disorders. However, individual heterogeneity of microbiota, strains playing dominant role diseases, interactions these microbial metabolites with central/peripheral systems still need exploration. This review summarizes driving neurodevelopmental disorders (autism spectrum disorder attention deficit/hyperactivity disorder), neurodegenerative diseases (Alzheimer's Parkinson's disease), mood (anxiety depression) recent years discusses current clinical preclinical microbe‐based interventions, including dietary intervention, probiotics, prebiotics, fecal transplantation. It also puts forward insufficient on provides framework for further

Language: Английский

Citations

15
Bifidobacteria with indole-3-lactic acid-producing capacity exhibit psychobiotic potential via reducing neuroinflammation DOI Creative Commons
Xin Qian, Qing Li,

Huiyue Zhu

et al.

Cell Reports Medicine, Journal Year: 2024, Volume and Issue: 5(11), P. 101798 - 101798

Published: Oct. 30, 2024

Language: Английский

Citations

14
Association between Gut Microbiota and Biological Aging: A Two-Sample Mendelian Randomization Study DOI Creative Commons
Chenglin Ye, Zhiqiang Li, Chun Ye

et al.

Microorganisms, Journal Year: 2024, Volume and Issue: 12(2), P. 370 - 370

Published: Feb. 11, 2024

Recent observational studies revealed an association between gut microbiota and aging, but whether are causally associated with the aging process remains unknown. We used a two-sample Mendelian randomization approach to investigate causal biological age acceleration using largest available GWAS summary data from MiBioGen consortium on acceleration. further conducted sensitivity analysis MR-PRESSO, MR-Egger regression, Cochran Q test, reverse MR analysis. Streptococcus (IVW, β = 0.16, p 0.0001) was Bioage Eubacterium (rectale group) 0.20, 0.0190), Sellimonas 0.06, 0.019), Lachnospira −0.18, 0.01) were suggestive of associations acceleration, latter being protective. Actinomyces 0.26, 0.0083), Butyricimonas 0.21, 0.0184), Lachnospiraceae (FCS020 0.24, 0.0194) Phenoage This study found that Further randomized controlled trials needed its role in process.

Language: Английский

Citations

11